Litigation Details for AngioScore, Inc. v. TriReme Medical, LLC (Fed. Cir. 2015)

AngioScore, Inc. v. TriReme Medical, LLC (Fed. Cir. 2015)

Docket		Date Filed	2015-10-27
Court	Court of Appeals for the Federal Circuit	Date Terminated	2016-11-08
Cause		Assigned To
Jury Demand		Referred To
Patents	11,975,022
Link to Docket	External link to docket

Details for AngioScore, Inc. v. TriReme Medical, LLC (Fed. Cir. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-10-27				External link to document

AngioScore v. TriReme Medical Patent Litigation: Federal Circuit Summary and Analysis

Last updated: August 29, 2026

AngioScore, Inc. v. TriReme Medical, LLC, Nos. 2016-1126 and 2016-1142, concerned patent infringement claims involving scoring angioplasty balloon catheters. The Federal Circuit addressed claim construction, infringement, patent validity, and the evidentiary basis for the district court's judgment. The appeal did not create an Orange Book exclusivity issue or a Hatch-Waxman Paragraph IV dispute. It was commercial-device patent litigation involving competing catheter technologies.

What was AngioScore v. TriReme Medical about?

AngioScore developed and commercialized scoring balloon catheters used in percutaneous transluminal angioplasty. A scoring balloon catheter uses external scoring or cutting elements to focus force against a stenotic lesion during balloon inflation. The technology is intended to improve lesion dilation and reduce uncontrolled balloon expansion.

AngioScore alleged that TriReme's competing catheter products infringed AngioScore patent claims covering the arrangement and operation of scoring elements associated with an angioplasty balloon. TriReme denied infringement and challenged the asserted claims on validity and claim-construction grounds.

The litigation involved technical limitations directed to the relationship among:

• The inflatable balloon;
• External scoring elements;
• Longitudinal or helical elements associated with the balloon;
• The manner in which those elements constrain or score a lesion; and
• Structural and functional relationships required by the asserted claims.

The case reached the Federal Circuit through consolidated appeals numbered 2016-1126 and 2016-1142.

Which companies were involved in the AngioScore litigation?

AngioScore was the patent owner and plaintiff. The company developed scoring balloon catheter products for peripheral and coronary vascular procedures.

TriReme Medical was the accused infringer and defendant. TriReme marketed competing interventional vascular products and disputed AngioScore's interpretation of the asserted patent claims.

The litigation was a competitor-versus-competitor dispute, rather than a generic pharmaceutical case. No abbreviated new drug application, biologic license application, biosimilar application, or FDA Orange Book listing was at issue.

What legal issues did the Federal Circuit consider?

The Federal Circuit's review focused on the relationship between claim meaning, infringement proof, and validity. The court examined whether the district court had correctly interpreted the asserted claims and whether the resulting judgment was supported by the record.

Claim construction

Claim construction was central because the asserted claims described both structural components and functional relationships. In device cases, a limitation that appears functional can materially narrow the scope of the claim if it requires the accused product to operate in a specified way.

The Federal Circuit evaluated the claim language in the context of the patent specification and prosecution history. The analysis followed the ordinary hierarchy of claim construction:

1. The words of the claims;
2. The written description;
3. The prosecution history; and
4. Extrinsic evidence only where necessary.

The court did not treat broad functional language as an automatic basis for expansive infringement rights. The accused device had to satisfy the claim as properly construed.

Infringement

AngioScore argued that TriReme's catheter met the limitations of the asserted claims. TriReme argued that its product used a different arrangement or operating relationship and therefore fell outside the claim scope.

The Federal Circuit's analysis illustrates a recurring medical-device litigation issue: minor differences in the placement, attachment, orientation, or operation of catheter components can determine infringement. A product may perform a similar clinical function while avoiding infringement if it does not contain the claimed structural relationship.

The court also examined the evidentiary record supporting infringement. Patent plaintiffs must prove infringement for every limitation, either literally or under the doctrine of equivalents. General similarity in product purpose is insufficient.

Validity

TriReme also contested the validity of the asserted claims. The Federal Circuit considered the district court's treatment of validity issues under the Patent Act, including the written-description and definiteness requirements where applicable to the claim language and specification.

The written-description inquiry asks whether the patent specification demonstrates that the inventors possessed the claimed invention as of the relevant filing date. Possession must be evaluated against the actual scope of the claims, not merely against the commercial product or a general description of the invention.

For medical devices, written-description disputes often arise when claims cover multiple arrangements of components but the specification illustrates only a limited set of embodiments. The commercial success of the product does not cure a deficient written description.

What was the Federal Circuit's disposition?

The Federal Circuit issued a mixed disposition in the consolidated appeals. It did not simply affirm all aspects of the district court's judgment. The appellate court affirmed some rulings, vacated or reversed other aspects, and remanded issues for further proceedings consistent with its opinion.

The practical significance was that the Federal Circuit required the district court to apply the appellate court's interpretation of the claims and its analysis of the evidentiary record. The opinion therefore affected both the infringement determination and the treatment of the patent defenses.

The decision should be read as a claim-scope case. It did not establish that all scoring balloon catheter products infringe AngioScore's patents. Nor did it hold that a competitor can avoid infringement merely by changing the product's marketing description. The controlling question remained whether the accused product satisfied the limitations of the properly construed claims.

How strong was the AngioScore patent estate?

The litigation showed that AngioScore had commercially relevant intellectual property around scoring balloon catheter architecture. The estate's value depended on claim scope, technical read-on, and the ability to prove infringement against competing designs.

Technical strengths

The patents addressed specialized catheter structures rather than a broad therapeutic concept. That type of protection can be valuable when:

• The patented component arrangement is necessary for the device's clinical performance;
• Competitors must use similar scoring mechanics to achieve comparable results;
• Manufacturing tolerances make design-around difficult; and
• The claims cover multiple attachment or orientation configurations.

Legal limitations

The estate also faced limitations typical of mechanical medical-device patents:

• Narrow claim language can reduce infringement coverage;
• Functional terms require careful proof of product operation;
• A competitor may change component placement without materially changing clinical use;
• Written-description and definiteness challenges can narrow claims; and
• Patent value may decline rapidly when alternative catheter architectures are commercially viable.

The Federal Circuit litigation did not establish a broad exclusionary right over the entire scoring-balloon market. Its effect was limited to the asserted claims and the accused TriReme products addressed in the case.

Did the case involve patent expiration or regulatory exclusivity?

No FDA regulatory exclusivity period was at issue. Unlike pharmaceutical litigation, the case did not involve:

• Orange Book-listed patents;
• New chemical entity exclusivity;
• New clinical investigation exclusivity;
• Pediatric exclusivity;
• Paragraph IV certifications;
• ANDA approval timing; or
• Biosimilar interchangeability.

Patent expiration still mattered commercially because medical-device protection is limited by the statutory patent term. The relevant term depends on each patent's filing and priority history, including any pre- or post-1995 transition rules and patent-term adjustment. The appellate opinion focused on litigation issues rather than presenting a consolidated patent-expiration schedule.

Were there Paragraph IV challenges or generic-entry risks?

No. TriReme was not a generic-drug applicant, and the case did not involve a Paragraph IV certification.

The commercial-entry risk was instead a medical-device design-around risk. TriReme could compete by:

• Altering the number or geometry of scoring elements;
• Changing how scoring elements attach to the balloon;
• Modifying the orientation of the elements;
• Using a different balloon or catheter construction; or
• Developing a clinically similar device outside the asserted claim limitations.

For device companies, this type of risk can be more significant than a conventional generic launch because market entry does not depend on FDA approval of an ANDA. A competing device may require its own regulatory pathway, but it can still enter without challenging an Orange Book patent.

What patent litigation lessons apply to medical-device companies?

Patent drafting

The case demonstrates the need to draft claims and specifications around multiple embodiments. A patent estate should include:

• Broad system claims;
• Narrow structural claims;
• Claims to attachment mechanisms;
• Claims to scoring-element geometry;
• Claims to balloon inflation behavior;
• Method-of-use claims; and
• Manufacturing claims where production steps create a meaningful barrier.

A specification that supports only one commercial embodiment may provide limited flexibility during litigation.

Product documentation

Infringement disputes often turn on product engineering records, testing, drawings, and expert analysis. Companies should preserve documentation showing:

• Component dimensions;
• Attachment methods;
• Design changes;
• Prototype development dates;
• Testing conditions;
• Manufacturing deviations; and
• The relationship between design choices and clinical performance.

Freedom-to-operate analysis

A competitor should not rely solely on a different product name or marketing claim. A proper freedom-to-operate review should map each component and operating relationship against every limitation of the asserted claims.

The AngioScore litigation also illustrates why claim charts must distinguish between:

• Literal infringement;
• Infringement under the doctrine of equivalents;
• Invalidity defenses;
• Unasserted patents in the same family; and
• Later-issued continuation claims.

How does AngioScore compare with pharmaceutical patent litigation?

Issue	AngioScore v. TriReme	Pharmaceutical patent litigation
Technology	Scoring angioplasty catheter	Drug or biologic
Regulatory pathway	Medical-device approval pathway	NDA, ANDA, BLA, or biosimilar pathway
Orange Book	Not applicable	Often central
Paragraph IV	Not applicable	Common in generic disputes
Primary risk	Design-around and component mapping	Regulatory approval and patent expiry
Infringement proof	Physical structure and operation	Composition, formulation, method, or manufacturing
Exclusivity	Patent-based	Patent plus FDA regulatory exclusivity
Competitor entry	New or modified device	Generic or biosimilar launch

The case is therefore more relevant to interventional-device patent strategy than to drug-pricing or generic-entry analysis.

What was the commercial impact of the litigation?

The litigation created potential exposure for TriReme through injunction risk, damages, litigation costs, and disruption of commercialization. For AngioScore, the value of the case depended on whether the asserted claims could be enforced against commercially meaningful competing products.

The Federal Circuit's mixed disposition reduced the likelihood that the litigation alone would establish complete market exclusion. The decision required continued district-court proceedings and left commercial outcomes dependent on the remaining claims, proof of infringement, and the scope of any subsequent judgment or settlement.

No broad market-wide injunction, pharmaceutical-style launch block, or regulatory exclusivity order resulted from the Federal Circuit decision itself.

Key Takeaways

• AngioScore v. TriReme involved competing scoring angioplasty catheter technologies.
• The case was decided under conventional medical-device patent principles, not Hatch-Waxman or biosimilar law.
• Claim construction and proof of each structural and functional limitation were central.
• Similar clinical purpose did not establish infringement.
• The Federal Circuit issued a mixed decision and remanded issues for further proceedings.
• The case illustrates the importance of drafting patent claims around alternative catheter structures and operating relationships.
• Commercial risk depended on claim scope and design-around feasibility rather than FDA Orange Book status.
• The litigation did not create a broad patent monopoly over all scoring balloon catheters.

FAQs

Did AngioScore v. TriReme involve a drug patent?

No. It involved patents covering scoring balloon catheters used in angioplasty procedures.

Was TriReme challenging an Orange Book patent?

No. TriReme was not pursuing an ANDA Paragraph IV challenge, and no Orange Book listing was at issue.

Did the Federal Circuit hold that all TriReme catheters infringed?

No. The court's analysis was limited to the asserted claims, the accused products, and the evidentiary record developed in the litigation.

Could TriReme avoid the patents through a catheter design-around?

Potentially. A design-around would depend on whether the modified catheter avoided every limitation of the properly construed claims, including limitations concerning component arrangement and operation.

Did the case establish a patent-expiration date for AngioScore's products?

No. The appellate decision addressed infringement and validity issues rather than providing a consolidated patent-term or product-exclusivity schedule.

References

1. United States Court of Appeals for the Federal Circuit. (2017). AngioScore, Inc. v. TriReme Medical, LLC, Nos. 2016-1126, 2016-1142. Federal Circuit opinions.

2. United States Patent and Trademark Office. (n.d.). Patent examination and patent term adjustment resources. https://www.uspto.gov

3. United States Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files.